Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

Cytel, a biometrics CRO and clinical trial software provider, announced that it will be adding a new location for clinical development in Basel, Switzerland. 

Cytel Adds New Clinical Software Site

PCI Pharma Services, a pharmaceutical outsourcing services provider, will acquire Millmount Healthcare, a pharmaceutical and healthcare contract packaging services provider, to expand its European services.

PCI Pharma Services to Acquire Millmount Healthcare

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

CDMOs have established strategies for handling new chemical entities with unknown biological activity.

Managing Potentially Potent APIs

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Mergers and acquisitions are positive for the CDMO industry, but there is a downside.

Up and Away, M&A

The acquisition broadens the CDMO’s preclinical and clinical offering to include bioanalytical and drug discovery services. 

ABL Acquisition Extends Ardena’s Early-Phase Offering

Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.


Cambrex Adds Reactors to Facility in Sweden

ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.

ADC Bio Invests $11 Million on Bioconjugation Facility

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Ajinomoto Althea Adds High Potency Capabilities

The acquisition adds to Catalent’s capabilities in biologics development, analytical services, manufacturing, and finished product supply. 

Catalent to Acquire Cook Pharmica for $950 Million

Matching the production requirements of a bio/pharma company with the manufacturing capabilities of a CMO is a delicate balance, requiring attitude shifts on both sides of the table.
